Recurrent meningioma
- 4 September 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 69 (10) , 969-973
- https://doi.org/10.1212/01.wnl.0000271382.62776.b7
Abstract
Background: Somatostatin receptors, especially the sst2A subtype, are present on most meningiomas. The addition of somatostatin inhibits meningioma growth in vitro in some studies. There have been anecdotal reports of octreotide inhibiting growth in meningiomas.Keywords
This publication has 9 references indexed in Scilit:
- Salvage chemotherapy With CPT-11 for recurrent meningiomaJournal of Neuro-Oncology, 2006
- Cerebrospinal fluid‐disseminated meningiomaCancer, 2005
- Temozolomide for treatment-resistant recurrent meningiomaNeurology, 2004
- Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningiomasJournal of Neurosurgery, 2002
- Visual improvement during octreotide therapy in a case of episellar meningiomaClinical Neurology and Neurosurgery, 1998
- The Treatment of Recurrent Unresectable and Malignant Meningiomas with Interferon Alpha-2BNeurosurgery, 1997
- Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2.Proceedings of the National Academy of Sciences, 1994
- Treatment of unresectable meningiomas with the antiprogesterone agent mifepristoneJournal of Neurosurgery, 1991
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989